[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Newcastle-upon-Tyne Hospitals NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,67,99,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100616709","local-field-potentials-in-dystonia-100616709",false,"NCT07309133","Local Field Potentials in Dystonia","Optimising Deep Brain Stimulation for Dystonia Using Local Field Potentials","LFP-DYT","Inclusion Criteria:\n\n* Age 18 years or older at screening.\n* Clear clinical diagnosis of primary dystonia (idiopathic or genetic forms).\n* Candidate for GPi DBS surgery for dystonia treatment.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Significant neurological or psychiatric disorder (including dementia) that would interfere with outcome evaluation.\n* Participation in a therapeutic research trial within the last year.\n* Diagnosis of functional (psychogenic) dystonia.","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to learn whether local field potential (LFP) signals recorded from the globus pallidus interna (GPi) using the Medtronic Percept™ deep brain stimulation (DBS) device can help optimize DBS programming for people with dystonia. The study will also explore whether LFP patterns can serve as a biomarker of disease activity and predict treatment response.\n\nThe main questions it aims to answer are:\n\nDo LFP peaks in the alpha-theta range reliably correlate with dystonia severity and clinical characteristics? Can LFP-based programming achieve similar or better clinical outcomes compared to traditional programming methods? How do LFP profiles change with stimulation and other treatments such as botulinum toxin or oral medications?\n\nResearchers will compare two programming approaches:\n\nTraditional programming based on clinical assessment and imaging. LFP-guided programming based on the site and characteristics of LFP peaks\n\nParticipants will:\n\nUndergo DBS surgery for dystonia as part of standard clinical care. Attend regular follow-up visits for DBS programming and outcome assessments. Complete clinical rating scales for dystonia severity, quality of life, cognition, and mood.\n\nTake part in neurophysiological assessments, including surface EMG, EEG, and reaction time tasks.\n\nHave LFP recordings collected using the Medtronic Percept™ device during clinic visits and, where possible, at home using device sensing features.\n\nThis study will help determine whether LFP analysis can shorten the time to optimal DBS settings and improve outcomes for people with dystonia.",[25,26,27],"Dystonia","Dystonia, Focal","Dystonia, Primary",[29,30,31,32,33,34],"Deep Brain Stimulation","DBS","Globus Pallidus Interna","Local Field Potentials","Neurostimulation","Neurophysiology","RECRUITING","2025-12-15",{"date":38,"type":39},"2025-12-30","ACTUAL",{"date":41,"type":39},"2025-09-04",{"date":43,"type":21},"2028-12",{"name":45,"class":46},"Newcastle-upon-Tyne Hospitals NHS Trust","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":47},"100371213","mitochondrial-donation-an-18-month-outcome-study-100371213","NCT04113447","Mitochondrial Donation: An 18 Month Outcome Study.","Inclusion Criteria:\n\nWomen will only be eligible if they meet all of the following criteria.\n\n* Women with confirmed mtDNA mutation\n* Suitable to undergo Mitochondrial Donation as a treatment (in line with HFEA license)\n* Informed Consent for the study obtained before Mitochondrial Donation treatment commences\n* Ability and willingness to adhere to the protocol including evaluation schedule\n* Willingness to make available information collected during pregnancy, delivery and up to the child's age of 18 months (corrected for gestational age)\n\nExclusion Criteria:\n\nWomen will not be eligible if they meet any of the following criteria\n\n* Declined Mitochondrial Donation as a treatment (in line with HFEA license)\n* Inability or unwillingness to adhere to the protocol including evaluation schedule\n* Unwillingness to make available information collected during pregnancy, delivery and up to the child's age of 18 months (corrected for gestational age)","FEMALE",{"count":20,"type":21},"The Investigator proposes to record the fetal and postnatal development of children conceived using Mitochondrial Donation (MD) and to perform expert assessment of development at 18 months (corrected for gestational age) using the internationally validated Bayley-III developmental assessment tool.",[58],"Mitochondrial Diseases","2025-07-16",{"date":61,"type":39},"2025-07-20",{"date":63,"type":39},"2017-11-01",{"date":65,"type":21},"2027-11-30",{"name":45,"class":46},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100591327","adult-sma-research-and-clinical-hub-100591327","NCT06978985","Adult SMA Research and Clinical Hub","Adult SMA REACH: Development and Implementation of a Standardised Data Set and Data Collection Research Study in the UK Adult SMA Population","REACH","Inclusion Criteria:\n\n* Age ≥16 years (when patients will begin the transition process to adulthood)\n* Genetically confirmed diagnosis of 5q SMA\n* Signed informed consent to take part in the study\n\nExclusion Criteria:\n\n* Non-5q SMA\n* No genetic confirmation\n* \\\u003C16 years of age\n* No signed informed consent or consent withdrawn","16 Years",{"count":77,"type":21},600,"Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular Atrophy (SMA). This study is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. Adult SMA REACH is funded by Biogen and Roche.\n\nCurrently, there are three drug treatments available for SMA in the UK: Zolgensma, Nusinersen and Risdiplam. Zolgensma is the only approved drug - Nusinersen and Risdiplam are currently available as part of Managed Access Agreements (MAA).",[80],"Spinal Muscular Atrophy (SMA)",[82,83,84,85,86,87,88,89],"SMA","Data collection","Adult SMA","SMA REACH","Data collection study","Spinal","Muscular Atrophy, Spinal","real-world data","2025-05-09",{"date":92,"type":39},"2025-05-18",{"date":94,"type":39},"2022-07-29",{"date":96,"type":21},"2027-04-30",{"name":45,"class":46},18,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":116,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100367440","myotubular-and-centronuclear-myopathy-patient-registry-100367440","NCT04064307","Myotubular and Centronuclear Myopathy Patient Registry","Inclusion Criteria:\n\n* Patients with a myotubular myopathy or centronuclear myopathy diagnosis, which has been confirmed via genetic testing or muscle biopsy.\n* Any carrier females of x-linked myotubular myopathy, especially if they have manifested myotubular myopathy type symptoms.\n* Any patient who is deceased, but who had a confirmed diagnosis.\n\nExclusion Criteria:\n\n\\- None",{"count":106,"type":21},500,"1 Year","The Myotubular and Centronuclear Myopathy Patient Registry (also referred to as the 'MTM and CNM Registry') is an international, patient-reported database specific to these conditions.\n\nMore details and online registration are available at www.mtmcnmregistry.org.",[110,111,112,113,114,115],"Myotubular Myopathy","Myotubular Myopathy 1","Myotubular (Centronuclear) Myopathy","Centronuclear Myopathy","Centronuclear Myopathy, X-Linked","X-linked Myotubular Myopathy",[117,118,119,120,121],"Registry","Patient Registry","Myotubular","Centronuclear","Myopathy","2025-04-07",{"date":124,"type":39},"2025-04-09",{"date":126,"type":39},"2013-03-26",{"date":128,"type":21},"2025-05",{"name":45,"class":46},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":47},"100506465","mobilise-d-extension-study-100506465","NCT05874739","Mobilise-D: Extension Study","Validating a Digital Mobility Assessment in Parkinson's Disease Using Wearable Technology - the Mobilise-D Extension Study.","Control Cohort:\n\nInclusion Criteria:\n\n* Aged 50 years or over\n* Able to walk 4 meters independently without walking aids\n* Anticipated availability for 12 months.\n* Ability to consent and comply with any study specific procedures.\n* Willingness to wear a wearable sensor for mobility monitoring\n* Able to read and write in first language in the respective country\n\nExclusion Criteria:\n\n* Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \\>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological or orthopaedic impairment that significantly impacts on gait\n* Patients with a clinical diagnosis of PD, COPD, proximal hip fracture or MS\n* History of dementia\u002Fsignificant cognitive impairment, or movement disorder (including essential tremor)\n\nPD Cohort\n\nInclusion Criteria:\n\n* Participant in the Mobilise-D Clinical Validation Study (CVS) PD Cohort - see below.\n\nCVS PD Cohort:\n\nInclusion criteria:\n\n* Aged 18 or over\n* Patients with the clinical diagnosis of PD according to the recent criteria of the Movement Disorder Society\n* Hoehn \\& Yahr stage I-III\n\nExclusion Criteria:\n\n* History consistent with Dementia with Lewy Bodies (DLB), atypical parkinsonian syndromes (including multiple system atrophy or progressive supranuclear palsy, diagnosed according to accepted criteria)\n* Repeated strokes or stepwise progression of symptoms, leading to a diagnosis of 'vascular parkinsonism'\n* Drug-induced Parkinsonism",true,{"count":139,"type":21},651,"The goal of this observational study is to investigate the ability of a mobility monitor to measure and predict outcomes in Parkinson's disease (PD). It is an extension of a previous study (the Mobilise-D Clinical Validation Study) and consists of an additional follow-up visit for PD participants and the recruitment of age matched control participants. The data will inform researchers about PD disease progression and normal changes in mobility associated with aging.",[142,143],"Parkinson Disease","Aging","2024-07-05",{"date":146,"type":39},"2024-07-08",{"date":148,"type":39},"2023-05-17",{"date":150,"type":21},"2025-07-28",{"name":45,"class":46},""]